Ken Griffin Immunocore Holdings PLC Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 27,300 shares of IMCR stock, worth $800,709. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,300

Previous 32,900 17.02%

Holding current value

$800,709

Previous $1.11 Million 23.79%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$30.06 - $41.49 $5.11 Million - $7.05 Million	-169,844 Reduced 74.18%	59,108 $1.84 Million
Q2 2024 Aug 14, 2024	BUY	$33.78 - $63.75 $5.64 Million - $10.6 Million	166,927 Added 269.13%	228,952 $7.76 Million
Q1 2024 May 15, 2024	SELL	$60.14 - $75.36 $10.7 Million - $13.4 Million	-178,331 Reduced 74.19%	62,025 $4.03 Million
Q4 2023 Feb 14, 2024	BUY	$42.85 - $69.5 $2.95 Million - $4.78 Million	68,784 Added 40.09%	240,356 $16.4 Million
Q3 2023 Nov 14, 2023	BUY	$49.5 - $66.6 $6.72 Million - $9.04 Million	135,695 Added 378.22%	171,572 $8.9 Million
Q2 2023 Aug 14, 2023	SELL	$48.54 - $61.64 $1.19 Million - $1.51 Million	-24,445 Reduced 40.52%	35,877 $2.15 Million
Q1 2023 May 15, 2023	SELL	$46.12 - $65.71 $6.42 Million - $9.15 Million	-139,266 Reduced 69.78%	60,322 $2.98 Million
Q4 2022 Feb 14, 2023	SELL	$45.51 - $65.08 $4.31 Million - $6.17 Million	-94,814 Reduced 32.21%	199,588 $11.4 Million
Q3 2022 Nov 14, 2022	BUY	$37.34 - $57.44 $7.84 Million - $12.1 Million	209,902 Added 248.4%	294,402 $13.8 Million

Others Institutions Holding IMCR

# of Institutions

141

Shares Held

41.4M

Call Options Held

197K

Put Options Held

451K

View Full List

About Immunocore Holdings plc

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.29B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

More about IMCR

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account